BioPharmSignal logoBioPharmSignal

Biotech News

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Biotherapeutics (BRNS)Barinthus BiotherapeuticsClinical readout

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no treatment-related SAEs The MAD portion of the trial, which includes a gluten challenge, is ongoing GERMANTOWN, Md.,

Related news

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

ERASErasca2026-09-10 12:00 EST

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

View all latest news

Barinthus Biotherapeutics

Immune-Tolerance Therapeutics Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation. SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver...

Recent company news

BRNSBarinthus Biotherapeutics2026-08-24 22:57 EST

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-03-13 12:00 EST

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Stock data

Close
0.74 USD
Market cap
26.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States